Breast Cancer Recurrence Risk Calculator
Estimate your breast cancer recurrence risk based on tumor characteristics, biomarkers, and treatment received. Understand your prognosis and treatment benefits.
Did our AI summary help? Let us know.
Why: This page explains what the Breast Cancer Recurrence Risk calculator does, what to enter, and how to read the results—without repeating the overview above.
How: Enter your values in the calculator fields below, keep units consistent, then run the calculation to see results and any step-by-step work shown on this page.
Run the calculator when you are ready.
✅ Low Risk Profile
Small, ER+, node-negative
Click to load
⚠️ Intermediate Risk
Moderate-size tumor, Grade 2
Click to load
🔴 Triple Negative
ER-, PR-, HER2-
Click to load
💜 HER2 Positive
HER2+ requiring targeted therapy
Click to load
📍 Node Positive
Multiple lymph nodes involved
Click to load
5-Year Recurrence
1.0%
10-Year Recurrence
1.6%
Risk Category
Recurrence Risk
Disease-Free Survival
10-Year Outcomes
| Factor | Your Value | Impact |
|---|---|---|
| Tumor Size | 1-2cm | Moderate |
| Lymph Nodes | Negative | Favorable |
| Grade | Grade 2 | Moderate |
| ER Status | Positive | Favorable |
| Ki-67 | Low (<14%) | Favorable |
Hormonal Therapy
-40%
Risk Reduction
Radiation
-30%
Risk Reduction
For informational purposes only — not medical advice. Consult a healthcare professional before acting on results.
Understanding Breast Cancer Recurrence
Understanding breast cancer recurrence risk is essential for treatment planning, surveillance scheduling, and patient counseling. This calculator integrates tumor biology, staging, and treatment factors to estimate individualized recurrence probabilities.
Key Takeaways
- ✓Tumor size, node status, grade, and receptor profile are the strongest predictors of recurrence.
- ✓ER-positive cancers have lower early recurrence but ongoing late risk that can extend beyond 10 years.
- ✓Modern targeted therapies have dramatically reduced recurrence for HER2-positive disease.
- ✓Lifestyle modifications can reduce recurrence risk by 20-30% when combined with standard treatment.
Did You Know?
Breast cancer is the most common cancer worldwide, with 2.3 million new diagnoses annually.
The Oncotype DX genomic test can predict chemotherapy benefit in ER-positive, node-negative patients, potentially sparing 70% from unnecessary treatment.
Triple-negative breast cancer (ER-/PR-/HER2-) has the highest early recurrence risk but rarely recurs after 5 years.
ER-positive cancers have a relatively constant recurrence rate of about 1-2% per year that persists for at least 20 years after diagnosis.
Immunotherapy has shown promising results in triple-negative breast cancer, with pathologic complete response rates of 50-60% in some trials.
Male breast cancer accounts for about 1% of all breast cancer cases but tends to be diagnosed at a later stage.
How Does Breast Cancer Recurrence Work?
Risk Factor Integration
The calculator combines tumor characteristics (size, grade, receptor status), patient factors (age, node involvement), and treatment data to compute a composite recurrence risk score. Each factor is weighted based on validated prognostic models.
Time-Dependent Risk
Recurrence risk is not constant over time. Triple-negative cancers have highest risk in years 1-3, while ER-positive cancers maintain steady risk for 15+ years. The calculator models these different temporal patterns by subtype.
Treatment Benefit Estimation
By comparing baseline risk against expected treatment benefit (chemotherapy, endocrine therapy, anti-HER2 agents), the calculator estimates the absolute risk reduction from each treatment modality, helping inform shared decision-making.
Expert Tips
Know Your Pathology
Have your complete pathology report available including tumor size, grade, node count, ER/PR/HER2 status, and Ki-67 if available.
Consider Genomic Testing
For ER-positive, node-negative disease, ask about Oncotype DX or MammaPrint to refine chemotherapy benefit prediction.
Plan Long-Term Follow-Up
ER-positive patients need surveillance for at least 10-15 years. Discuss extended endocrine therapy (beyond 5 years) with your oncologist.
Lifestyle Matters
Regular exercise, healthy weight, and limited alcohol intake reduce recurrence risk. These benefits are additive to standard medical treatment.
Breast Cancer Recurrence Comparison
| Subtype | 5-Year Recurrence | 10-Year Recurrence | Treatment Impact |
|---|---|---|---|
| ER+/HER2- | 5-15% | 10-25% | Endocrine therapy: -40-50% |
| ER+/HER2+ | 5-10% | 8-18% | Endocrine + anti-HER2: -60% |
| ER-/HER2+ | 10-20% | 12-22% | Chemo + anti-HER2: -50% |
| Triple Negative | 20-40% | 22-42% | Chemo: -20-30% |
Frequently Asked Questions
What factors affect breast cancer recurrence?
Major factors include tumor size, lymph node involvement, tumor grade, hormone receptor status (ER/PR), HER2 status, Ki-67 proliferation rate, age at diagnosis, and treatment received. Node-positive and high-grade tumors carry the highest recurrence risk.
What is the 5-year recurrence rate for breast cancer?
Five-year recurrence rates vary widely: Stage I ER-positive cancers have approximately 5-10% recurrence, while Stage III triple-negative cancers may exceed 30-40%. Hormone receptor-positive cancers have lower early recurrence but continued risk beyond 5 years.
How does ER/PR status affect recurrence?
Estrogen receptor (ER) and progesterone receptor (PR) positive cancers respond to endocrine therapy, reducing recurrence by 40-50%. However, ER-positive cancers have a unique pattern of late recurrence, with ongoing risk for 15-20 years after diagnosis.
What is the role of HER2 status in recurrence?
HER2-positive cancers were historically aggressive, but targeted therapies like trastuzumab have dramatically improved outcomes, reducing recurrence by approximately 50%. HER2-positive cancers that are also hormone receptor-positive have the best overall prognosis with dual-targeted therapy.
How does treatment reduce recurrence risk?
Chemotherapy reduces recurrence by 20-30%, endocrine therapy by 40-50% for hormone-positive cancers, and anti-HER2 therapy by about 50% for HER2-positive disease. Radiation after surgery reduces local recurrence by 50-70% depending on the type of surgery.
Can lifestyle changes reduce recurrence?
Yes, regular exercise (150+ minutes/week) reduces recurrence risk by 20-30%. Maintaining a healthy BMI, limiting alcohol, and following a plant-rich diet also contribute. These lifestyle factors are particularly impactful for hormone receptor-positive breast cancers.
Key Statistics
Official Data Sources
Medical Disclaimer
This calculator is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions based on calculator results.
Related Calculators
Breast Cancer Risk Calculator
Assess breast cancer risk using the Gail Model risk factors
HealthBreastfeeding Calorie Calculator
Calculate additional calorie needs while breastfeeding
HealthA-a Gradient Calculator
Calculate the Alveolar-arterial (A-a) oxygen gradient to assess oxygenation efficiency. Helps differentiate between pulmonary and extrapulmonary causes of...
HealthAdvanced ABI Calculator (Ankle-Brachial Index)
Comprehensive Ankle-Brachial Index calculator with multiple measurement methods, advanced PAD risk assessment, exercise testing capability, cardiovascular...
HealthABSI Calculator (A Body Shape Index)
Calculate your A Body Shape Index (ABSI) to assess health risks and mortality prediction based on waist circumference, height, and weight. Get personalized...
HealthAbsolute Eosinophil Count (AEC) Calculator
Calculate Absolute Eosinophil Count from CBC with differential. Assess eosinophilia severity, identify potential allergic, parasitic, or autoimmune...
Health